Healthcare Technology
Kane Biotech Publishes Real-World Data on revyve Wound Gel
Kane Biotech Inc. (TSXV: KNE) has announced the publication of a peer-reviewed study evaluating its revyve Antimicrobial Wound Gel in patients with chronic and complex wounds. The prospective observational case series, published in the International Wound Journal, followed 17 adults with 28 wounds for up to 12 weeks. Wound types included diabetic foot ulcers, venous…
A $28.9B Sensor Patch Forecast Meets Dexcom and iRhythm Reality
A market research firm says the market for skin-worn health sensors will more than triple in five years. Wissen Research’s new report, announced October 13, puts the global sensor patch market at $7.9 billion in 2026 and projects it will reach $28.9 billion by 2031. That works out to a compound annual growth rate (CAGR)…
Why Biopsy Device Market Estimates Disagree So Sharply
A market research firm says the global biopsy devices business is growing. Just not quickly. Mordor Intelligence, in a press release issued October 13, 2026, estimates the market at USD 2.33 billion this year and projects it will reach USD 2.83 billion by 2031. That works out to a compound annual growth rate (CAGR), the…
TempraMed Links VIVI Cap Smart to Apple Health and Google Fit
TempraMed Technologies Ltd. (CSE: VIVI; OTCQB: TMPTF; FSE: 9DY) announced that its VIVI Cap Smart medication-protection device now supports connectivity with Apple Health and Google Fit. The October 5 update advances TempraMed’s effort to combine temperature protection with digital tracking for insulin pens, GLP-1 therapies and other injectable medications. VIVI Cap Smart is designed to…
GRAIL’s Galleri Test Heads to FDA Panel After Staff Review
GRAIL Inc. (Nasdaq: GRAL) is scheduled to bring its Galleri multi-cancer blood test before a U.S. Food and Drug Administration advisory panel on September 23, 2026, following the release of agency briefing materials that identified no outstanding panel questions in several core review areas. The FDA’s Molecular and Clinical Genetics Panel will discuss and vote…
Telo Genomics Reports Higher MRD Detection in Myeloma Study
Telo Genomics Corp. (TSXV: TELO; OTCQB: TDSGF) has reported clinical research results showing that its experimental blood-based TELO-MRD assay detected residual multiple myeloma cells in a higher proportion of matched samples than a bone-marrow test. The September 15 announcement covered 42 samples matched by patient and collection date. TELO-MRD detected circulating myeloma cells in 39…
Inside the Federal Review That Could Reshape Lab AI
Federal regulators are reconsidering how a set of lab-testing rules written in 1992 should handle artificial intelligence, and the group representing the country’s clinical lab professionals just weighed in. The outcome could matter for investors well beyond any one company: the two largest publicly traded U.S. commercial labs, plus at least one AI-native diagnostics company,…
What Are Organoids? The Lab-Grown “Mini-Organs” Changing Drug Testing
Traditional preclinical drug testing has relied heavily on two-dimensional cell cultures — cells grown as a flat layer in a laboratory dish — and animal models, both of which imperfectly represent how a drug will actually behave in complex human tissue. Organoids offer a fundamentally different approach: three-dimensional, lab-grown tissue structures that self-organize to mimic…
Inside St. Joseph’s New AI-Powered Chest CT Reading Tool
Coreline Soft, a South Korean medical AI company that trades on the KOSDAQ exchange under ticker 384470, and INFINITT North America announced on August 21 the deployment of a chest CT-based AI reading workflow at St. Joseph’s Health, an academic hospital system in Paterson, New Jersey. It is the second major North American deployment for…
What Is RNA Interference (RNAi)? The Gene-Silencing Technology Powering a New Drug Class
While CRISPR captured public attention for editing DNA directly, a related but mechanistically distinct technology quietly built its own approved drug class by intervening one step later in the gene expression process — at the RNA level rather than the DNA level. RNA interference (RNAi) therapeutics silence specific disease-causing genes by preventing their RNA instructions…
